Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by fredgoodwinsonon Apr 11, 2020 3:44am
417 Views
Post# 30898491

Paper published 8th of April

Paper published 8th of April

Thanks again Eog.

 

That PDT/X-Ray one-two in Section 7 must be making Glioblastoma really nervous.

 

There's no mention of Tf in that particular section but aside from the Osmium complexes the stand-out from this paper is the transformative extent to which the result of pre-incubation of TLD-1433 in apo-Tf dwarves TLD-1433 on it's`own in terms of performance safety and capability. 

 

Already made clear to us before the moratatorium on announcements relating to scientific progress that pre-incubation enabled both the systemic administration and effective accumulation of the PS in the tumour via the blood/brain barrier.

 

So in the Clinic surely not TLD-1433 but instead Rutherrin - the drug that dare not speak its`name.

 
Bullboard Posts